Mellitus
Boston
About Mellitus
Mellitus develops a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis, and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarker called Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $13.8M
- Last round: Undisclosed (May 2019)
- Website: mellitusllc.com
- Phone: 617-758-4146
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/mellitus-37917 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.